Improvements in the Pharmacological Profile of Diazepam by KRM-II-81, an Imidazodiazepine Positive Allosteric Modulator of 2/3-Containing GABAA Receptors: Preclinical Data Predict Enhanced Efficacy for Epilepsy, Chronic Pain, Anxiety, and Depression

Improvements in the Pharmacological Profile of Diazepam by KRM-II-81, an Imidazodiazepine Positive Allosteric Modulator of 2/3-Containing GABAA Receptors: Preclinical Data Predict Enhanced Efficacy for Epilepsy, Chronic Pain, Anxiety, and Depression. Pharmaceutical Sciences And Biomedical Analysis Journal. 2019; 2(1):117. Improvements in the Pharmacological Profile of Diazepam by KRM-II-81, an Imidazodiazepine Positive Allosteric Modulator of  2/3-Containing GABAA Receptors: Preclinical Data Predict Enhanced Efficacy for Epilepsy, Chronic Pain, Anxiety, and Depression

[1]  Jodi L. Smith,et al.  The Positive Allosteric Modulator of α2/3-Containing GABAA Receptors, KRM-II-81, Is Active in Pharmaco-Resistant Models of Epilepsy and Reduces Hyperexcitability after Traumatic Brain Injury , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[2]  Jodi L. Smith,et al.  The value of human epileptic tissue in the characterization and development of novel antiepileptic drugs: The example of CERC-611 and KRM-II-81 , 2019, Brain Research.

[3]  M. Hall,et al.  The Opioid Crisis and the Future of Addiction and Pain Therapeutics , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[4]  Donal N. Gorman,et al.  Analgesic potential of PF-06372865, an α2/α3/α5 subtype-selective GABAA partial agonist, in humans. , 2019, British journal of anaesthesia.

[5]  P. Davis,et al.  The α2,3-selective potentiator of GABAA receptors, KRM-II-81, reduces nociceptive-associated behaviors induced by formalin and spinal nerve ligation in rats , 2019, Pharmacology Biochemistry and Behavior.

[6]  R. M. Owen,et al.  Design and Identification of a Novel, Functionally Subtype Selective GABAA Positive Allosteric Modulator (PF-06372865). , 2019, Journal of medicinal chemistry.

[7]  D. Buhl,et al.  Pronounced antiepileptic activity of the subtype‐selective GABAA‐positive allosteric modulator PF‐06372865 in the GAERS absence epilepsy model , 2019, CNS neuroscience & therapeutics.

[8]  K. Gee,et al.  Positive allosteric modulators of nonbenzodiazepine &ggr;-aminobutyric acidA receptor subtypes for the treatment of chronic pain , 2018, Pain.

[9]  D. Airey,et al.  Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo [1,5-a][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABAA receptors: Improved bioavailability enhances anticonvulsant efficacy , 2018, Neuropharmacology.

[10]  G. Dawson,et al.  Evidence That Sedative Effects of Benzodiazepines Involve Unexpected GABAA Receptor Subtypes: Quantitative Observation Studies in Rhesus Monkeys , 2018, The Journal of Pharmacology and Experimental Therapeutics.

[11]  Hoon-Chul Kang,et al.  Adverse Events During Perampanel Adjunctive Therapy in Intractable Epilepsy , 2018, Journal of clinical neurology.

[12]  J. Fisher,et al.  An antidepressant-related pharmacological signature for positive allosteric modulators of α2/3-containing GABAA receptors , 2018, Pharmacology Biochemistry and Behavior.

[13]  Donal N. Gorman,et al.  Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABAA receptor positive allosteric modulator PF‐06372865 , 2018, British journal of pharmacology.

[14]  L. Arnold,et al.  Further evaluation of the potential anxiolytic activity of imidazo[1,5-a][1,4]diazepin agents selective for α2/3-containing GABAA receptors , 2017, Pharmacology Biochemistry and Behavior.

[15]  R. Chou,et al.  Systemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline , 2017, Annals of Internal Medicine.

[16]  J. Fisher,et al.  Antinociceptive Effects of a Novel α2/α3-Subtype Selective GABAA Receptor Positive Allosteric Modulator. , 2017, ACS chemical neuroscience.

[17]  C. Halldin,et al.  GABAA receptor occupancy by subtype selective GABAAα2,3 modulators: PET studies in humans , 2016, Psychopharmacology.

[18]  J. Witkin,et al.  Synthesis and Characterization of a Novel γ-Aminobutyric Acid Type A (GABAA) Receptor Ligand That Combines Outstanding Metabolic Stability, Pharmacokinetics, and Anxiolytic Efficacy. , 2016, Journal of medicinal chemistry.

[19]  P. Muglia,et al.  NS11821, a partial subtype-selective GABAA agonist, elicits selective effects on the central nervous system in randomized controlled trial with healthy subjects , 2016, Journal of psychopharmacology.

[20]  William T. Ralvenius,et al.  Analgesia and unwanted benzodiazepine effects in point-mutated mice expressing only one benzodiazepine-sensitive GABAA receptor subtype , 2015, Nature Communications.

[21]  Y. Daali,et al.  GABAergic modulation in central sensitization in humans: a randomized placebo-controlled pharmacokinetic–pharmacodynamic study comparing clobazam with clonazepam in healthy volunteers , 2015, Pain.

[22]  P. Maruff,et al.  The central nervous system effects of the partial GABA-Aα2,3 -selective receptor modulator AZD7325 in comparison with lorazepam in healthy males. , 2014, British journal of clinical pharmacology.

[23]  K. Gee,et al.  Limited central side effects of a β-subunit subtype-selective GABAA receptor allosteric modulator , 2014, Journal of psychopharmacology.

[24]  J. Barrow,et al.  Classics in chemical neuroscience: diazepam (valium). , 2014, ACS chemical neuroscience.

[25]  U. Rudolph,et al.  GABAA receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism. , 2014, Annual review of pharmacology and toxicology.

[26]  P. Skolnick.  Anxioselective anxiolytics: on a quest for the Holy Grail. , 2012, Trends in pharmacological sciences.

[27]  J. Cook,et al.  The role of &agr;1 and &agr;5 subunit-containing GABAA receptors in motor impairment induced by benzodiazepines in rats , 2012, Behavioural pharmacology.

[28]  R. Schoemaker,et al.  The effects of TPA023, a GABAAα2,3 subtype-selective partial agonist, on essential tremor in comparison to alcohol , 2012, Journal of psychopharmacology.

[29]  J. Conry,et al.  Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome , 2011, Neurology.

[30]  F. Knoflach,et al.  Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes , 2011, Nature Reviews Drug Discovery.

[31]  J. Atack,et al.  GABAA receptor subtype-selective modulators. I. α2/α3-selective agonists as non-sedating anxiolytics. , 2011, Current topics in medicinal chemistry.

[32]  David Taylor,et al.  Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis , 2011, BMJ : British Medical Journal.

[33]  P. Czobor,et al.  A Multicenter, Placebo‐Controlled, Double‐Blind, Randomized Study of Efficacy and Safety of Ocinaplon (DOV 273,547) in Generalized Anxiety Disorder , 2010, CNS neuroscience & therapeutics.

[34]  J. Belluzzi,et al.  Limiting Activity at β1-Subunit-Containing GABAA Receptor Subtypes Reduces Ataxia , 2010, Journal of Pharmacology and Experimental Therapeutics.

[35]  Kelly R. Tan,et al.  Neural bases for addictive properties of benzodiazepines , 2010, Nature.

[36]  G. Dawson,et al.  Reducing Abuse Liability of GABAA/Benzodiazepine Ligands via Selective Partial Agonist Efficacy at α1 and α2/3 Subtypes , 2010, Journal of Pharmacology and Experimental Therapeutics.

[37]  J. Baron,et al.  Benzodiazepine Binding Site Occupancy by the Novel GABAA Receptor Subtype-Selective Drug 7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in Rats, Primates, and Humans , 2010, Journal of Pharmacology and Experimental Therapeutics.

[38]  J. Atack.  GABAA receptor alpha2/alpha3 subtype-selective modulators as potential nonsedating anxiolytics. , 2010, Current topics in behavioral neurosciences.

[39]  N. Mirza,et al.  Developing analgesics by enhancing spinal inhibition after injury: GABAA receptor subtypes as novel targets. , 2009, Trends in pharmacological sciences.

[40]  B. Roth,et al.  Antiseizure activity of novel gamma-aminobutyric acid (A) receptor subtype-selective benzodiazepine analogues in mice and rat models. , 2009, Journal of medicinal chemistry.

[41]  H. Zeilhofer,et al.  Genuine Antihyperalgesia by Systemic Diazepam Revealed by Experiments in Gaba a Receptor Point-mutated Mice , 2008 .

[42]  R. Olsen,et al.  GABAA receptors: Subtypes provide diversity of function and pharmacology , 2009, Neuropharmacology.

[43]  J. Atack.  Subtype-selective GABA(A) receptor modulation yields a novel pharmacological profile: the design and development of TPA023. , 2009, Advances in pharmacology.

[44]  S. C. Licata,et al.  Contribution of α1 subunit-containing γ-aminobutyric acidA (GABAA) receptors to motor-impairing effects of benzodiazepines in squirrel monkeys , 2009, Psychopharmacology.

[45]  Andrea Tone,et al.  The Age of Anxiety: A History of America's Turbulent Affair with Tranquilizers , 2008 .

[46]  W. Sieghart,et al.  Are GABAA Receptors Containing α5 Subunits Contributing to the Sedative Properties of Benzodiazepine Site Agonists? , 2008, Neuropsychopharmacology.

[47]  J. Gerven,et al.  Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA α2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers , 2007 .

[48]  N Collinson,et al.  An Inverse Agonist Selective for α5 Subunit-Containing GABAA Receptors Enhances Cognition , 2006, Journal of Pharmacology and Experimental Therapeutics.

[49]  G. Dawson,et al.  TPA023 [7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an Agonist Selective for α2- and α3-Containing GABAA Receptors, Is a Nonsedating Anxiolytic in Rodents and Primates , 2006, Journal of Pharmacology and Experimental Therapeutics.

[50]  G. Dawson,et al.  7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine: a functionally selective gamma-aminobutyric acid(A) (GABA(A)) alpha2/alpha3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal models. , 2005, Journal of medicinal chemistry.

[51]  G. Dawson,et al.  Evidence for a Significant Role of α3-Containing GABAA Receptors in Mediating the Anxiolytic Effects of Benzodiazepines , 2005, The Journal of Neuroscience.

[52]  P. Czobor,et al.  Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[53]  K. Wafford.  GABAA receptor subtypes: any clues to the mechanism of benzodiazepine dependence? , 2005, Current opinion in pharmacology.

[54]  W. Haefely.  Pharmacology of the benzodiazepine receptor , 2004, European archives of psychiatry and neurological sciences.

[55]  C. Allgulander,et al.  Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder , 2001, British Journal of Psychiatry.

[56]  I Tobler,et al.  Diazepam-induced changes in sleep: role of the alpha 1 GABA(A) receptor subtype. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[57]  T. Rülicke,et al.  Molecular and neuronal substrate for the selective attenuation of anxiety. , 2000, Science.

[58]  R. Mckernan,et al.  Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor α1 subtype , 2000, Nature Neuroscience.

[59]  S. Woods,et al.  Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans. , 1999, European journal of pharmacology.

[60]  J. Benson,et al.  Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. , 1999, Nature.

[61]  W. Hevers,et al.  The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes. , 1998, Molecular neurobiology.

[62]  M. Bousoño,et al.  SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. , 1997, Journal of sex & marital therapy.

[63]  S. Koslow,et al.  Onset of antidepressant activity: Reexamining the structure of depression and multiple actions of drugs , 1996, Depression and anxiety.

[64]  N. Ryan,et al.  Fluoxetine for childhood anxiety disorders. , 1994, Journal of the American Academy of Child and Adolescent Psychiatry.

[65]  B. Denis,et al.  [Hepatitis induced by alpidem (Ananxyl). Four cases, one of them fatal]. , 1994, Gastroenterologie clinique et biologique.

[66]  J. Fritschy,et al.  GABAA-receptor subtypes differing in alpha-subunit composition display unique pharmacological properties. , 1992, Advances in biochemical psychopharmacology.

[67]  G. Mawer,et al.  Respiratory and sedative effects of clobazam and clonazepam in volunteers. , 1990, British journal of clinical pharmacology.

[68]  P. Morselli,et al.  Clinical studies with the new anxiolytic alpidem in anxious patients: An overview of the European experiences , 1988, Pharmacology Biochemistry and Behavior.

[69]  B. Maletzky.  Anxiolytic Efficacy of Alprazolam Compared to Diazepam and Placebo , 1980, The Journal of international medical research.

[70]  G. Aden,et al.  Alprazolam compared to diazepam and placebo in the treatment of anxiety. , 1980, The Journal of clinical psychiatry.

[71]  B. Beer,et al.  Resolution of two biochemically and pharmacologically distinct benzodiazepine receptors , 1979, Pharmacology Biochemistry and Behavior.

[72]  S. Paul,et al.  Labelling of benzodiazepine receptors in vivo , 1978, Nature.

[73]  C. Braestrup,et al.  Specific benzodiazepine receptors in rat brain characterized by high-affinity (3H)diazepam binding. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[74]  G. Fischbach,et al.  Chlordiazepoxide selectively augments GABA action in spinal cord cell cultures , 1977, Nature.

[75]  H. Parry,et al.  National patterns of psychotherapeutic drug use. , 1973, Archives of general psychiatry.

[76]  J. Overall,et al.  DIAZEPAM IN NEWLY ADMITTED SCHIZOPHRENICS. , 1963, Diseases of the nervous system.

[77]  G. A. Heise,et al.  The psychosedative properties of methaminodiazepoxide. , 1960, The Journal of pharmacology and experimental therapeutics.